Table 5.
Distribution of the exposure to beta-blockers by molecule.
| Beta-Blocker Molecule, n (%) | |
|---|---|
| Cardioselective beta-blocker before melanoma diagnosis | |
| atenolol | 10 (23.8) |
| bisoprolol | 5 (11.9) |
| labetalol | 1 (2.4) |
| metoprolol | 24 (57.1) |
| nebivolol | 2 (4.8) |
| Wide spectrum beta-blocker before melanoma diagnosis | |
| carteolol a | 2 (13.3) |
| carvedilol | 1 (6.7) |
| propranolol | 4 (26.7) |
| sotalol | 1 (6.7) |
| timolol a | 7 (46.7) |
| Cardioselective beta-blocker after melanoma diagnosis | |
| atenolol | 4 (19) |
| bisoprolol | 3 (14.3) |
| cotenolol | 1 (4.8) |
| metoprolol | 12 (57.1) |
| nebivolol | 1 (4.8) |
| Wide spectrum beta-blocker after melanoma diagnosis | |
| propranolol | 1 (33.3) |
| carvedilol | 2 (66.7) |
a Eye drop formulation.